[Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT]

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as an observational study.

Biochemical control has been the main objective in the treatment of acromegaly; however, GH and IGF-1 levels do not necessarily translate into clinical response, as they fail to account for the complexity of symptoms and patients' perceptions.

Why It Was Studied

The SAGIT instrument was developed to assist in assessing the status and evolution of the disease in patients with acromegaly and facilitate decision-making.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

Observational, unicentric study, conducted in 2022 at a referral hospital in León, Guanajuato, Mexico.

What Was Measured

The SAGIT instrument was developed to assist in assessing the status and evolution of the disease in patients with acromegaly and facilitate decision-making.

The subject headings attached to it are Acromegaly, Somatostatin, Octreotide, Peptides, Cyclic, Insulin-Like Growth Factor I and Gels.

The authors tagged it with the keywords Acromegalia, Factor I del Crecimiento Similar a la Insulina, Lanreotide, Lanreótida, Octreótida and SAGIT.

What This Means in Plain Language

This is an observational study of Octreotide and Somatostatin.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Revista medica del Instituto Mexicano del Seguro Social), a journal based in Mexico.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.